Ganther J M, Kreling D H
Sonderegger Research Center, School of Pharmacy, University of Wisconsin, Madison, USA.
J Am Pharm Assoc (Wash). 2000 May-Jun;40(3):378-83. doi: 10.1016/s1086-5802(16)31086-5.
To examine consumer risk perceptions for generic prescription drugs used to treat different types of medical conditions, and to explore the relationship between risk perceptions and the amount of cost savings required before consumers would purchase the generic version of a prescription drug.
Cross-sectional mail survey.
Metropolitan area in central Wisconsin.
Random sample of 500 consumers age 18 and older.
None.
Responses to 16 items on 8-page questionnaire. None.
The response rate was 71.4%. The percentage of respondents who perceived that generic prescription drugs were riskier than brand name products varied from 14.2% to 53.8%, depending on the medical condition being treated. Significantly larger cost savings were required for consumers to purchase generic prescription drugs with higher perceived risk.
Financial incentives to use generic prescription drugs may be successful, even for consumers who perceive generic drugs to be riskier than brand name prescription drugs. As the perceived level of risk increases, larger cost savings are required.
研究消费者对用于治疗不同类型医疗状况的非专利处方药的风险认知,并探讨风险认知与消费者购买非专利处方药版本前所要求的成本节省金额之间的关系。
横断面邮寄调查。
威斯康星州中部的大都市区。
500名18岁及以上消费者的随机样本。
无。
对8页问卷上16个项目的回答。无。
回复率为71.4%。根据所治疗的医疗状况,认为非专利处方药比品牌药风险更高的受访者比例在14.2%至53.8%之间。对于那些认为风险较高的非专利处方药,消费者需要显著更多的成本节省才会购买。
使用非专利处方药的经济激励措施可能会成功,即使对于那些认为非专利药比品牌处方药风险更高的消费者也是如此。随着感知风险水平的增加,需要更大的成本节省。